Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Total Non-Current Liabilities (2024 - 2025)

Evommune (EVMN) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $10.4 million as the latest value for Q3 2025.

  • Quarterly Total Non-Current Liabilities changed N/A to $10.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Sep 2025, changed N/A year-over-year, with the annual reading at $28.0 million for FY2024, N/A changed from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $10.4 million at Evommune, down from $28.0 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $28.0 million in Q4 2024, with the low at $10.4 million in Q3 2025.